SF-9-2 是一种 PD-L1/PD-1 结合抑制剂(IC50 = 24.9 nM),可抑制 SK-N-SH 细胞的上皮间质转化、迁移、侵袭和增殖,并诱导其凋亡和细胞周期停滞,同时通过 MAPK 信号通路阻断 PD-L1 诱导的 SK-N-SH 细胞生长,恢复 GSK-3β 活性并通过泛素-蛋白酶体通路增强 PD-L1 降解,还可作为免疫检查点抑制剂阻断 PD-L1 以恢复 T 细胞功能,在 SK-N-SH NOG 小鼠模型中抑制肿瘤生长且无明显毒性,因此可用于神经母细胞瘤研究。
产品编号: MS-B92524 CAS No.: 3053768-78-5 分子式: C30H27F2N3O3 分子量: 515.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SF-9-2 是一种 PD-L1/PD-1 结合抑制剂(IC50 = 24.9 nM),可抑制 SK-N-SH 细胞的上皮间质转化、迁移、侵袭和增殖,并诱导其凋亡和细胞周期停滞,同时通过 MAPK 信号通路阻断 PD-L1 诱导的 SK-N-SH 细胞生长,恢复 GSK-3β 活性并通过泛素-蛋白酶体通路增强 PD-L1 降解,还可作为免疫检查点抑制剂阻断 PD-L1 以恢复 T 细胞功能,在 SK-N-SH NOG 小鼠模型中抑制肿瘤生长且无明显毒性,因此可用于神经母细胞瘤研究。

生物实验数据

生物活性 SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM) that inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation while inducing apoptosis and cell cycle arrest in SK-N-SH cells, blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway, restores GSK-3β activity and enhances PD-L1 degradation via the ubiquitin-proteasome pathway, and also acts as an immune checkpoint inhibitor by blocking PD-L1 to restore T cell function, thereby inhibiting tumor growth in the SK-N-SH NOG mouse model without obvious toxicity and being useful for neuroblastoma research.
IC50 & Target

GSK-3β

 

Caspase 3

 

体外研究
(In Vitro)

SF-9-2 (0.5-16 μM, 48 小时) 对 SK-N-SH (IC50 = 5.9 μM) 和 SK-N-AS 细胞 (IC50 = 8.67 μM) 表现出显著的抑制活性,但对 SH-SY5Y 和 SK-N-BE (2) 细胞的抑制作用较小,对正常细胞 MRC-5 (IC50 = 12.15 μM) 表现出较弱的细胞毒性作用。
SF-9-2 (1-6 μM, 24 小时) 可抑制 SK-N-SH 细胞增殖、迁移、侵袭和上皮-间质转化 (EMT),并诱导其发生线粒体依赖性细胞凋亡和细胞周期停滞。
SF-9-2 (2.5-8 μM, 24-48 小时) 可通过靶向 ERK 信号通路抑制 SK-N-SH 细胞中的 MAPK 通路并下调 PD-L1 水平。
SF-9-2 (2.5-5 μM, 24 小时) 诱导 SK-N-SH 细胞中 GSK-3β 介导的 PD-L1 内化和蛋白酶体降解。
SF-9-2 (2.25-200 nM) 在过表达 PD-1 和 Fc-PD-L1 蛋白的 293T 细胞中可降低荧光信号,有效阻断的 PD-1/PD-L1 免疫检查点。
SF-9-2 (1-16 μM, 48 小时) 可提高 PBMCs 中 IFN-γ 的分泌水平,在 1、2 和 4 μM 浓度下对 PBMCs 无明显毒性。
SF-9-2 (1-8 μM, 48 小时) 可表现出直接的肿瘤杀伤活性和 T 细胞介导的针对 SK-N-SH 细胞的细胞毒作用。

Cell Migration Assay

Cell Line: SK-N-SH cells
Concentration: 1 μM, 2 μM, 4 μM
Incubation Time: 24 h
Result: Inhibited the migration, reduced the number of cells passing through the chamber, with the migration rate in the 1, 2, 4 μM group was 73.3%, 43.0%, 13.4%, respectively.

Western Blot Analysis

Cell Line: SK-N-SH cells
Concentration: 2.5 μM, 5 μM
Incubation Time: 24 h, 48 h
Result: Up-regulated the expressions of N-cadherin and E-cadherin, and down-regulated the expressions of β-catenin, and vimentin.
Reduced the Bcl-2/BAX ratio and increased the cleavage of Caspase 3.
Reduced the phosphorylation levels of ERK and JNK, and increased the phosphorylation level of p38 at 48 h.
Reduced PD-L1 levels at 5 μM.
Reduced the level of p-GSK-3β (Ser9), weakened the inhibitory effect of p-ERK on GSK-3β to a certain extent, and promoted the activation of GSK-3β at 5 μM.

Apoptosis Analysis

Cell Line: SK-N-SH cells
Concentration: 1 μM, 3 μM, 6 μM
Incubation Time: 24 h
Result: Induced apoptosis, with the proportion of early and late apoptotic cells increasing in a dose-dependent manner.

Cell Cycle Analysis

Cell Line: SK-N-SH cells
Concentration: 1 μM, 3 μM, 6 μM
Incubation Time: 24 h
Result: Increased the proportion of cells in the G1/S phase while decreasing the percentage of cells in the G2 phase.

Western Blot Analysis

Cell Line: PD-L1 knockdown SK-N-SH cells
Concentration: 2.5 μM, 5 μM
Incubation Time: 24 h
Result: Was weaker than that in normal SK-N-SH cells for the downregulation of ERK phosphorylation.

Immunofluorescence

Cell Line: SK-N-SH cells
Concentration: 2.5 μM
Incubation Time: 24 h
Result: Reduced PD-L1 on the cell surface (red fluorescence) and internalized it into the cytoplasm as compound concentration increases.

ELISA Assay

Cell Line: PBMCs
Concentration: 1 μM, 2 μM, 4 μM
Incubation Time: 48 h
Result: Increased the secretion level of IFN-γ at 4 μM.
体内研究
(In Vivo)

SF-9-2 (20-40 mg/kg,腹腔注射,每天一次,21 天) 抑制 NOG 小鼠模型中的 SK-N-SH 肿瘤生长。

Animal Model: SK-N-SH tumor (50 million cells/mL, s.c.) female NOG mice (5 weeks old, 17-20 g) model
Dosage: 20 mg/kg, 40 mg/kg
Administration: i.p., once a day, 21 days
Result: Inhibited tumor growth, with tumor inhibition rates of 23.79% (20 mg/kg) and 69.45% (40 mg/kg) respectively.
Had no effects on body weight or mortality, exhibited no apparent nephrotoxicity or hepatotoxicity.

化学信息

分子量 515.55
分子式 C30H27F2N3O3
CAS No. 3053768-78-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础